Editas reports 58% HBG1/2 editing in NHPs after single tLNP dose at 5 months

Editas Medicine, Inc.

Mean on-target editing of 58% in HSCs at 5 months post single IV dose of proprietary tLNP, exceeding ≥25% therapeutic threshold.
Data presented at EHA 2025; supports in vivo approach for sickle cell disease and beta thalassemia.
Biodistribution shows significant liver de-targeting vs. standard LNPs in NHPs.
Uses AsCas12a to edit HBG1/2 promoters, mimicking hereditary persistence of fetal hemoglobin.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.